Therapeutic strategies targeting ALK5 have been considered particularly in the context of diseases characterized by excessive fibrosis, such as idiopathic pulmonary fibrosis, liver fibrosis, cardiovascular disease, and certain cancers [32–34]. This evidence concerns the gene TGFBR1 and cancer.